Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Rousselot

Showing results (71-80 of 195) with videos related to

Pageof 20
Sort By:
Blood|February 11, 2003
CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and junDFotini Nicolaou, Jens M Teodoridis, Heiyoung Park, et al.
Clinical Pharmacology and Therapeutics|May 29, 2025
BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of VigibaseAurélie Cabannes-Hamy, Rayan Kabirian, Floriane Jochum, et al.
American Journal of Hematology|December 31, 2013
Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapseSylvain Pilorge, Sophie Rigaudeau, Florence Rabian, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2006
BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemiaNicolas Boissel, Delphine Rea, Vannary Tieng, et al.
Nature|September 3, 2015
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonistsStéphane Prost, Francis Relouzat, Marc Spentchian, et al.
Journal of Wound Care|March 6, 2025
Chemotherapy-induced leg ulcers: a case seriesMarion Rousselot, Emmanuel Mahé, Patricia Senet, et al.
Blood|February 27, 2014
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 studyNeil P Shah, François Guilhot, Jorge E Cortes, et al.
Haematologica|February 16, 2023
Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia <i>FLT3</i>-ITD patientsNicolas Vignal, Loïs Kelly, Etienne Lengline, et al.
Leukemia Research|July 8, 2010
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily aloneFranck E Nicolini, Sandrine Hayette, Laurence Legros, et al.
Blood|June 14, 2021
PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALLGuillaume P Andrieu, Milena Kohn, Mathieu Simonin, et al.
Pageof 20

Showing results (71-80 of 195) with videos related to

Sort By:
Pageof 20
Blood|February 11, 2003
CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and junDFotini Nicolaou, Jens M Teodoridis, Heiyoung Park, et al.
Clinical Pharmacology and Therapeutics|May 29, 2025
BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of VigibaseAurélie Cabannes-Hamy, Rayan Kabirian, Floriane Jochum, et al.
American Journal of Hematology|December 31, 2013
Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapseSylvain Pilorge, Sophie Rigaudeau, Florence Rabian, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2006
BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemiaNicolas Boissel, Delphine Rea, Vannary Tieng, et al.
Nature|September 3, 2015
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonistsStéphane Prost, Francis Relouzat, Marc Spentchian, et al.
Journal of Wound Care|March 6, 2025
Chemotherapy-induced leg ulcers: a case seriesMarion Rousselot, Emmanuel Mahé, Patricia Senet, et al.
Blood|February 27, 2014
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 studyNeil P Shah, François Guilhot, Jorge E Cortes, et al.
Haematologica|February 16, 2023
Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia <i>FLT3</i>-ITD patientsNicolas Vignal, Loïs Kelly, Etienne Lengline, et al.
Leukemia Research|July 8, 2010
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily aloneFranck E Nicolini, Sandrine Hayette, Laurence Legros, et al.
Blood|June 14, 2021
PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALLGuillaume P Andrieu, Milena Kohn, Mathieu Simonin, et al.
Pageof 20